The dual role of OTUD3 in cancer: mechanisms and therapeutic implications Authors: Jialin Zhang, Lu Lu, Wenchang Xu, Na Zhou, Yongfeng Song Published: 2025 ABSTRACT OTUD3 (Ovarian Tumor Domain-Containing Protein 3), a deubiquitinating enzyme, has emerged as a pivotal and context-dependent regulator in cancer pathogenesis, exhibiting a striking functional duality as either a tumor suppressor or oncoprotein across different cancer types. Acting as a dual regulator, it influences key cellular processes—including proliferation, apoptosis, immune evasion, and metabolic reprogramming—by stabilizing specific substrates such as PTEN, p53, GRP78, YY1, and PD-L1. Its role extends to modulating inflammatory signaling, antiviral immunity, and metabolic homeostasis, highlighting its broad functional versatility. The development of OTUD3-targeted inhibitors like Rolapitant, Rupatadine, and OTUDin3 shows promise in preclinical models, particularly in combination with immunotherapy. However, its tissue-specific duality poses both challenges and opportunities for therapeutic intervention. Further research is needed to elucidate OTUD3’s mechanistic networks and advance its clinical translation as a prognostic biomarker and therapeutic target in precision oncology. Introduction Cancer remains a leading cause of mortality worldwide, with its pathogenesis involving dysregulation in critical cellular processes such as proliferation [1, 2], apoptosis [3, 4], and immune surveillance [5, 6]. Despite advancements in conventional treatments like surgery, radiotherapy, and chemotherapy, challenges including high recurrence rates and the development of therapy resistance persist, underscoring the urgent need for novel therapeutic targets [7]. A growing body of evidence highlights the significance of deubiquitinating enzymes (DUBs) in carcinogenesis [8]. Among them, the ovarian tumor domain-containing protein OTUD3 has garnered increasing attention as a pivotal and substrate-dependent regulator across multiple cancer types [9]. In oncology, OTUD3 exhibits a remarkable functional duality, acting as either a tumor suppressor or an oncoprotein depending on the cellular context and specific cancer type. For instance, OTUD3 exerts tumor-suppressive effects in breast and esophageal cancers by stabilizing PTEN and ZFP36 [9, 10], yet it promotes tumor growth and metastasis in lung cancer and large B-cell lymphoma (DLBCL) by stabilizing GRP78 and MYL12A [11, 12]. This dichotomous functionality underscores its central and complex role in tumor biology. As a crucial deubiquitinating enzyme, OTUD3 regulates protein stability and function by removing ubiquitin chains, thereby playing a pivotal role in cellular signaling [13], cell cycle progression [14], and maintaining protein homeostasis [15]. Its substrates encompass key players in diverse pathways, directly linking OTUD3 activity to fundamental cancer hallmarks. Furthermore, the initiation and progression of many cancers are closely linked to chronic inflammation [16], immune evasion [17], and metabolic reprogramming, processes in which OTUD3 is increasingly implicated. Overall, OTUD3 stands as a central and multifaceted player in cancer pathogenesis. Its profound influence on core cellular processes and its substrate-dependent functionality present both a challenge and a significant opportunity for targeted therapy. Focused research on OTUD3 is not just warranted but imperative, as it holds the key to deepening our understanding of cancer and, more importantly, to unlocking a new class of targeted therapies designed to modulate its activity for clinical benefit [18]. The role and mechanisms of OTUD3 in cancer Epidemiological perspectives on OTUD3 in cancers In China, cancer represents a formidable and heterogeneous public health burden (Table 1). Among the most prevalent and lethal malignancies are lung, colorectal, and liver cancers, which consistently rank as leading causes of both cancer incidence and mortality [19]. Additionally, cancers such as those of the esophagus and lymphoma contribute significantly to cancer-related deaths, while thyroid cancer, despite its high diagnosis rate, is associated with a comparatively favorable survival outcome [19]. This diverse cancer profile, encompassing malignancies with vastly different etiologies and prognoses, underscores the critical need for biomarkers that can help decipher disease progression and predict patient outcomes across distinct cancer types. Table 1Incidence and mortality of selected cancers in China [19]Cancer typeCrude incidence rate (per 100,000)ASIR (The age-standardized incidence rate, per 100,000)Crude mortality rate (per 100,000)Hepatocellular Carcinoma (HCC)26.0415.0322.42Colorectal Cancer (CRC)36.6320.1017.00Lung Cancer75.1340.7851.94Esophageal Cancer15.878.3213.28Lymphoma6.033.772.95Thyroid Cancer33.0224.640.82 Table 1Incidence and mortality of selected cancers in China [19]Cancer typeCrude incidence rate (per 100,000)ASIR (The age-standardized incidence rate, per 100,000)Crude mortality rate (per 100,000)Hepatocellular Carcinoma (HCC)26.0415.0322.42Colorectal Cancer (CRC)36.6320.1017.00Lung Cancer75.1340.7851.94Esophageal Cancer15.878.3213.28Lymphoma6.033.772.95Thyroid Cancer33.0224.640.82 Incidence and mortality of selected cancers in China [19] OTUD3 plays a critical and complex role in cancer epidemiology, serving as a powerful predictor of patient survival. Its impact, however, is cancer-type specific. In breast cancer, high OTUD3 expression is a favorable prognostic marker, associated with significantly longer recurrence-free survival (p = 0.0072) in an analysis of 200 patient samples [20], and better overall survival in a cohort of 156 patients (p = 0.010) [21]. Similarly, in glioma, high OTUD3 levels in 697 analyzed cases were linked to longer overall survival (p = 7.111 × 10⁻³)10. Conversely, OTUD3 acts as an oncogene in other malignancies. High OTUD3 expression predicts poorer survival in lung adenocarcinoma and is associated with shorter overall survival in cholangiocarcinoma, based on a study of 79 patients (p < 0.05) [22]. This dual role is further evidenced in colorectal cancer, where high OTUD3 in 90 patient tissues correlated with significantly shorter overall survival (p = 0.0209) [23]. These compelling data, drawn from thousands of patient analyses, firmly establish OTUD3 as a crucial and clinically relevant prognostic biomarker across multiple cancers. Gene localization and expression profiles of the OTUD3 OTUD3 is a deubiquitinating enzyme belonging to the ovarian tumor (OTU) family, primarily responsible for removing ubiquitin modifications from substrate proteins to maintain their stability. As a key regulator in cancer pathogenesis, OTUD3 exerts tissue-specific and context-dependent roles in multiple tumor types [24]. It functions as a critical modulator of ribosomal ubiquitination, reversing ZNF598-mediated ubiquitination of 40 S ribosomal proteins including eS10 and uS10 [25]. In addition to its emerging significance in cancers, OTUD3 also participates in neurodegenerative processes, such as cleaving K6-linked polyubiquitin chains on UBB + 1 [26], and modulating dopaminergic neuron survival in Parkinson’s models [27]. The OTUD3 gene is located in 1p36.13. It has been detected in various tissues. In hepatocellular carcinoma (HCC), OTUD3 expression shows dual patterns: one study reports significant downregulation in tumor tissues, associated with poor prognosis and sorafenib resistance [28], while another indicates OTUD3 is highly expressed and linked to aggressive clinicopathological features [29]. Similarly, such contradictory expression patterns are also observed in colorectal cancer (CRC). In CRC, studies present conflicting findings on OTUD3 expression: one indicates its downregulation via microRNA-32, supporting a tumor-suppressive role [30], whereas another reports significant upregulation in tumors, linking it to poor prognosis through YY1 stabilization [23]. In lung cancer, OTUD3 is consistently upregulated across multiple studies, promoting tumor growth and poor survival, and is regulated by the ubiquitin ligase CHIP [11, 31, 32]. In breast cancer, OTUD3 expression is downregulated and acts as a tumor suppressor, positively correlating with PTEN levels and inversely with Akt activation; its expression is further suppressed by miR-520 h, contributing to paclitaxel resistance [21, 33, 34]. A recent prognostic model study further supports its tumor-suppressive potential in breast cancer, where high OTUD3 expression is significantly associated with better patient survival [35]. In other cancers, OTUD3 is often upregulated—such as in lymphoma, and cholangiocarcinoma—where it promotes tumor progression, but is downregulated in esophageal cancer due to nicotine exposure [9, 12, 22]. Its role remains less clear in cancers like uveal melanoma [36] (Table 2). Table 2Dual expression of OTUD3 in cancersCancer typeOTUD3 expression changePrimary function/AssociationHepatocellular CarcinomaUpregulated & DownregulatedSignificantly downregulated in tumor tissues; associated with poor prognosis and sorafenib resistance [28]Highly expressed and linked to aggressive clinicopathological features [29]Colorectal CancerUpregulated & DownregulatedActs as a tumor suppressor by deubiquitinating and stabilizing PTEN; its downregulation promotes cell proliferation, migration, and suppresses apoptosis [30]Acts as an oncogene by deubiquitinating and stabilizing the transcription factor YY1, thereby promoting cancer cell proliferation, tumor growth, and progression [23]Lung CancerUpregulatedPromotes tumor growth and is associated with poor survival; its expression is regulated by the ubiquitin ligase CHIP [11,31,32]Breast CancerDownregulatedFunctions as a tumor suppressor; positively correlates with PTEN levels and inversely with Akt activation. Its expression is suppressed by miR-520 h, contributing to paclitaxel resistance [21, 33, 34]Esophageal CancerDownregulatedExpression is suppressed due to nicotine exposure [9]Lymphoma, CholangiocarcinomaUpregulatedPromotes tumor progression [12, 22]Uveal MelanomaUnclearIts role remains less defined [36] Table 2Dual expression of OTUD3 in cancersCancer typeOTUD3 expression changePrimary function/AssociationHepatocellular CarcinomaUpregulated & DownregulatedSignificantly downregulated in tumor tissues; associated with poor prognosis and sorafenib resistance [28]Highly expressed and linked to aggressive clinicopathological features [29]Colorectal CancerUpregulated & DownregulatedActs as a tumor suppressor by deubiquitinating and stabilizing PTEN; its downregulation promotes cell proliferation, migration, and suppresses apoptosis [30]Acts as an oncogene by deubiquitinating and stabilizing the transcription factor YY1, thereby promoting cancer cell proliferation, tumor growth, and progression [23]Lung CancerUpregulatedPromotes tumor growth and is associated with poor survival; its expression is regulated by the ubiquitin ligase CHIP [11,31,32]Breast CancerDownregulatedFunctions as a tumor suppressor; positively correlates with PTEN levels and inversely with Akt activation. Its expression is suppressed by miR-520 h, contributing to paclitaxel resistance [21, 33, 34]Esophageal CancerDownregulatedExpression is suppressed due to nicotine exposure [9]Lymphoma, CholangiocarcinomaUpregulatedPromotes tumor progression [12, 22]Uveal MelanomaUnclearIts role remains less defined [36] Dual expression of OTUD3 in cancers Significantly downregulated in tumor tissues; associated with poor prognosis and sorafenib resistance [28] Highly expressed and linked to aggressive clinicopathological features [29] Acts as a tumor suppressor by deubiquitinating and stabilizing PTEN; its downregulation promotes cell proliferation, migration, and suppresses apoptosis [30] Acts as an oncogene by deubiquitinating and stabilizing the transcription factor YY1, thereby promoting cancer cell proliferation, tumor growth, and progression [23] Deubiquitination regulation and enzymatic activity of OTUD3 OTUD3’s functional role varies between tumor suppression and promotion across different cancer types. This functional duality is well exemplified by its actions on distinct substrates. For instance, it deubiquitinates PTEN in breast, colon and papillary thyroid cancers, thereby inhibiting the PI3K/AKT pathway and tumorigenesis [21, 33, 37]; it also deubiquitinates SMAD7, thereby inhibiting the TGF-β signaling pathway and suppressing the invasion and metastasis of breast cancer cells [20]. Conversely, in lung cancer, OTUD3 exerts an oncogenic function by deubiquitinating and stabilizing GRP78, which promotes tumor growth and metastasis [11, 18, 31, 32]. Similarly, in HCC, OTUD3 stabilizes ACTN4 to drive progression [29], while also deubiquitinating eIF2α to suppress stress response and sorafenib resistance [28]. Beyond these, OTUD3’s regulatory scope extends to other pivotal substrates and cancers. It deubiquitinates the transcription factor YY1 to facilitate CRC progression [23], and stabilizes both MYL12A and PD-L1 in lymphoma to promote tumor survival and immune evasion [12]. Furthermore, OTUD3 stabilizes ZFP36 in esophageal cancer [9] and ARID3A in cholangiocarcinoma [22], underscoring its broad impact. OTUD3 also influences fundamental biological processes beyond oncology, such as inhibiting tumor cell proliferation by deubiquitinating KPTN to modulate the mTOR pathway [13], and regulating the innate immune response by targeting Mitochondrial Antiviral Signaling Protein (MAVS) [38, 39] and STING [40]. This diverse functionality highlights OTUD3 as a central player in cellular signaling with dual roles in cancer. Mechanisms of OTUD3 in regulating metabolism, cell cycle, apoptosis and immune responses OTUD3 maintains metabolic balance by controlling the stability of key proteins in fatty acid, glucose, and iron metabolism [15, 41]. It also directly regulates the cell cycle and apoptosis, influencing cell growth and death, especially under drug treatment or other stresses [10, 14, 18, 29, 30]. OTUD3’s role in immunity is particularly complex. It fine-tunes innate immune responses by targeting major signaling hubs. For example, it deubiquitinates MAVS to prevent excessive inflammation [39]. Conversely, OTUD3 plays a dual role in antiviral immunity: it suppresses responses to RNA viruses by removing ubiquitin chains from RIG-I/MDA5 [38], while it enhances defense against DNA viruses by stabilizing the sensor protein cGAS through deubiquitination [42]. The combined effects of these functions make OTUD3 a key regulator in disease occurrence and development. Regulation of the cell cycle is essential for controlling cell proliferation and tumor development. OTUD3 affects cell cycle progression by deubiquitinating and stabilizing cycle-related proteins. In breast cancer, OTUD3 stabilizes the cell cycle inhibitor p21, thereby inhibiting proliferation [14]. Conversely, in colorectal cancer, PLK1-mediated phosphorylation enhances OTUD3’s ability to deubiquitinate and stabilize YY1, thereby supporting tumor progression [23]. This dual role makes OTUD3 a potential therapeutic target in oncology (Table 3). Table 3Dual role of OTUD3 in cell cycleCancer typeOncogenic/Tumor suppressiveMolecular mechanismTarget proteinOutcomePotential therapeutic strategyBreast CancerTumor SuppressiveDeubiquitinates and stabilizes p21p21Inhibits cell proliferationActivate OTUD3 to enhance p21 stability [14]Breast CancerTumor SuppressiveMaintains p53 stabilityp53p53 deficiency drives malignant cyclingRestore OTUD3 expression to stabilize p53 [14]Colorectal CancerOncogenicPLK1-phosphorylated OTUD3 deubiquitinates YY1YY1Drives tumor progressionBlock OTUD3-PLK1 interaction or inhibit YY1 activity [23] Table 3Dual role of OTUD3 in cell cycleCancer typeOncogenic/Tumor suppressiveMolecular mechanismTarget proteinOutcomePotential therapeutic strategyBreast CancerTumor SuppressiveDeubiquitinates and stabilizes p21p21Inhibits cell proliferationActivate OTUD3 to enhance p21 stability [14]Breast CancerTumor SuppressiveMaintains p53 stabilityp53p53 deficiency drives malignant cyclingRestore OTUD3 expression to stabilize p53 [14]Colorectal CancerOncogenicPLK1-phosphorylated OTUD3 deubiquitinates YY1YY1Drives tumor progressionBlock OTUD3-PLK1 interaction or inhibit YY1 activity [23] Dual role of OTUD3 in cell cycle Apoptosis, a programmed cell death process, plays a critical role in breast cancer development. OTUD3 acts as a tumor suppressor by deubiquitinating and stabilizing p53, which enhances p21 expression, induces cell cycle arrest, and increases cisplatin-induced apoptosis. Downregulation of OTUD3 is associated with decreased p53 levels and poor patient prognosis [14]. Additionally, OTUD3 indirectly promotes apoptosis by stabilizing PTEN. miR-520 h-mediated suppression of OTUD3 accelerates PTEN degradation, activating pro-survival AKT signaling and conferring chemoresistance. Restoring OTUD3 expression stabilizes PTEN, suppresses AKT phosphorylation, and enhances paclitaxel-induced apoptosis [21]. Clinically, low OTUD3 expression correlates with unfavorable outcomes in breast cancer patients, underscoring its importance in apoptosis regulation [14, 21]. Thus, beyond regulating proliferation, OTUD3 is a pivotal modulator of apoptotic pathways. OTUD3 also serves as a crucial immune regulator. It modulates immune signaling pathways and influences immune cell functions within the tumor microenvironment, affecting immune evasion, T cell activation, and responses to immunotherapy. Through its deubiquitination activity, OTUD3 regulates protein stability and signaling pathways essential for metabolic homeostasis. It is involved in carbohydrate and lipid metabolism, energy balance, and iron metabolism, playing a significant role in metabolic diseases such as obesity, diabetes, and neurodegenerative disorders. The role of OTUD3 in cancer pathogenesis OTUD3 in inflammation OTUD3 functions as a critical molecular nexus, linking chronic inflammation to cancer progression by fine-tuning core inflammatory pathways (Fig. 1). Fig. 1Inflammation-related diseases and mechanisms of OTUD3 Inflammation-related diseases and mechanisms of OTUD3 OTUD3 acts as a critical and versatile regulator of inflammation. In intestinal inflammation, OTUD3 binds STING and removes K27-linked ubiquitin chains, thereby inhibiting STING signaling and preventing excessive type I interferon production. Risk-associated variants impair this function, exacerbating inflammation. Furthermore, in lung inflammation, OTUD3 deubiquitinates and stabilizes PTEN, suppressing the PI3K/AKT pathway and contributing to inflammatory injury. Conversely, in antiviral immunity, OTUD3 stabilizes and activates cGAS by removing inhibitory ubiquitin chains, amplifying the cGAS-STING pathway and interferon responses. The role of OTUD3 in inflammation and inflammatory diseases OTUD3 was first implicated in inflammatory processes through genome-wide association studies (GWAS) in Korean and European populations, which identified the OTUD3 locus as a susceptibility region for inflammatory bowel disease (IBD) [43]. Although the lead SNP rs4654903 is upstream of OTUD3 and in linkage disequilibrium with variants near other genes, OTUD3 emerged as a strong functional candidate due to its high expression in immune tissues [43–45]. Subsequent functional studies revealed that OTUD3, clustering with other IBD-associated genes such as IFIH1 and NFKB1, regulates type I interferon and antiviral responses in intestinal epithelial cells [46]. Further research established a concrete mechanism: OTUD3 is highly expressed in colonic fibroblasts, where it deubiquitinates and inhibits STING activation upon stimulation by microbiota-derived 3’3’-cGAMP. This protective role is compromised by ulcerative colitis-associated OTUD3 variants (rs758098056 and rs10799593), which impair deubiquitination activity, leading to enhanced STING signaling, excessive IFN-β production, and aggravated colitis—as validated in mouse models and human patients [40].Thus, OTUD3 acts as a critical regulator of host–microbiota interactions in intestinal inflammation. The critical role of OTUD3 in curbing inflammation appears to be an evolutionarily conserved principle, as compelling cross-species evidence demonstrates. In cattle, a 200-bp loss-of-function deletion within the OTUD3 coding sequence was exclusively identified in animals susceptible to clinical mastitis [47]. This variant is thought to cripple the ability of mammary epithelial cells to mount an effective, controlled innate immune response against invading pathogens. The striking parallel between the role of OTUD3 in sterile intestinal inflammation in humans and in infection-driven mastitis in cattle highlights its broad and fundamental significance as a regulator of anti-infection immunity. In summary, cumulative evidence from human genetics, mechanistic studies, and comparative genomics solidifies OTUD3’s status as a phylogenetically conserved modulator of inflammation. Its involvement in disparate inflammatory contexts—from sterile intestinal inflammation to infection-driven mastitis—not only underscores its broad functional significance but also invites further exploration into its detailed mechanisms and its potential as a therapeutic target across a spectrum of inflammatory diseases. Modulation of core inflammatory pathways OTUD3 is increasingly recognized as a critical modulator of inflammatory signaling, deftly fine-tuning immune responses through its influence on central pathways such as the cGAS–STING axis and PI3K/AKT. As a deubiquitinating enzyme, it directly edits ubiquitin chains on key signaling proteins, thereby regulating their stability and activity in inflammatory contexts. Consequently, even subtle changes in OTUD3’s expression or activity can profoundly alter cellular behavior and immune outcomes [40, 42, 48]. In the context of ulcerative colitis (UC), OTUD3 directly binds to STING via its OTU domain and removes K27-linked polyubiquitin chains, suppressing STING activation and downstream TBK1-IRF3 phosphorylation. This action curbs the production of type I interferons (e.g., IFN-β) and interferon-response genes (IRGs) in colonic fibroblasts. Notably, UC-risk variants (e.g., R90Q in humans, R89Q in mice) render OTUD3 incapable of cleaving K27-ubiquitin chains on STING, leading to hyperactivation of the STING-IFN-β pathway. Furthermore, microbiota-derived 3’3’-cGAMP enters fibroblasts via the volume-regulated anion channel (VRAC), and OTUD3 deficiency amplifies this STING-driven inflammatory response [40]. Beyond its role in restraining STING in colitis, OTUD3 also exerts a potent enhancing effect on the cGAS–STING pathway. It directly binds to and deubiquitinates cGAS, removing inhibitory K27- and K48-linked chains. This stabilizes the cGAS protein and boosts its enzymatic activity, leading to amplified production of the second messenger cGAMP and potent activation of the downstream STING–IRF3 signaling cascade. The result is a robust production of type I interferons (e.g., IFN-β) and chemokines (e.g., CXCL10). OTUD3’s role is so integral that its loss cripples the antiviral response, dampening IFN-β and CXCL10 production and allowing for increased viral replication [42]. The regulatory influence of OTUD3 extends to the PI3K/AKT pathway, particularly in lung inflammation. Here, OTUD3 deubiquitinates and stabilizes the tumor suppressor PTEN, which serves as a key negative regulator of PI3K/AKT signaling. This action impairs lung endothelial cell function and fuels an inflammatory milieu, marked by elevated levels of IL-1β, IL-6, IL-4, and IL-13. Intriguingly, a potential intervention has emerged: extracellular vesicles from bone marrow stromal cells (BMSCs), loaded with miR-34c-5p, can downregulate OTUD3. This promotes PTEN degradation and effectively attenuates lung injury and inflammation, highlighting the therapeutic potential of targeting this axis [48]. Overall, OTUD3 does not play a simple on-off switch in inflammation. Instead, it functions as a sophisticated integrator of inflammation signals. Its ability to sculpt the stability of diverse substrates, allows it to dictate inflammatory outcomes across different tissues and diseases, making it a compelling target for therapeutic intervention. Facilitation of chronic Inflammation-to-Cancer transition Chronic inflammation is a well-established driver of malignant transformation, leveraging common pathways such as oxidative stress and DNA damage. Emerging as a central node in this process across multiple cancer types is the deubiquitinating enzyme OTUD3. When dysregulated, OTUD3 can act as a molecular switch, tilting the inflammatory microenvironment toward tumor promotion. The mechanistic underpinnings of OTUD3 involve the stabilization of key oncogenic clients. Notably, the OTUD3-YY1 axis provides a compelling link between inflammatory signals and CRC progression, consistent with YY1 upregulation in inflammation-associated cancers [23]. Similarly, the pro-tumorigenic GSK3β-OTUD3-ARID3A axis offers a plausible explanation for how chronic biliary inflammation, a known risk factor for cholangiocarcinoma, fuels cancer development [22]. The context-dependent roles of OTUD3 are further illuminated in other inflammation-associated cancers. In HCC, which often arises on a background of chronic hepatitis (HBV, HCV, or NAFLD) [49–52], OTUD3 plays a paradoxical role: it can inhibit the integrated stress response to reduce chemotherapy resistance, yet it also promotes HCC growth and metastasis by stabilizing ACTN4 [28, 29]. Elsewhere, in gastric cancer, the focus shifts to persistent H. pylori infection, which causes inflammation-mediated DNA damage and p53 mutation [53]. Similarly, the pathogenesis of colitis-associated CRC, driven by IBD, features a distinct sequence of genetic alterations, including early TP53 mutations, with late APC inactivation playing critical roles [54–56]. Importantly, OTUD3’s function extends beyond epithelial cancer cells to the tumor microenvironment. A recent discovery shows that in UC, OTUD3 within colonic fibroblasts restrains microbiota-driven STING activation. When this protective mechanism is disrupted by UC-risk genetic variants, it exacerbates intestinal inflammation and fibrosis—key processes in the inflammation-to-cancer sequence [40]. Collectively, OTUD3 stands out as a pivotal molecular orchestrator of the chronic inflammation-to-cancer transition. Through its dysregulation, it stabilizes an array of oncogenic proteins and transcription factors, while in stromal cells, it modulates microbiota-driven inflammatory signaling, thereby directly coupling OTUD3 to pre-cancerous processes. The evidence positions OTUD3 as a central transducer of persistent inflammatory signals into pro-tumorigenic outcomes. OTUD3 in immune OTUD3 is a key driver of immune evasion in cancer (Fig. 2). It promotes tumor immune escape by deubiquitinating and stabilizing PD-L1, which suppresses T-cell function. Additionally, OTUD3 plays a dual role in antiviral immunity, suppressing RNA virus responses via MAVS while enhancing DNA virus defense via cGAS. Its upregulation across cancers like DLBCL stabilizes PD-L1, inhibiting cytotoxic T cells. Consequently, OTUD3 is a promising immunotherapeutic target, with inhibitors like Rupatadine shown to degrade PD-L1 and restore anti-tumor immunity. Fig. 2Mechanisms of OTUD3 in Immune Regulation Mechanisms of OTUD3 in Immune Regulation OTUD3 promotes tumor immune evasion through the deubiquitination and stabilization of PD-L1, which in turn suppresses T cell function. In antiviral immunity, however, OTUD3 exhibits a dual role: it dampens the immune response against RNA viruses by deubiquitinating MAVS in the RIG-I/MDA5 pathway, while it enhances the detection of DNA viruses by stabilizing cGAS and amplifying the cGAS-STING signaling cascade. Furthermore, OTUD3 is associated with high-risk uveal melanoma (UM) and contributes to an immunosuppressive tumor microenvironment. Impairment of Anti-Tumor immune cell function A key mechanism by which tumors evade immunity involves the suppression of T cell function through OTUD3 upregulation. Notably, OTUD3 enhances the stability of PD-L1 via deubiquitination, strengthening this critical immune checkpoint axis. By preventing PD-L1 degradation, OTUD3 contributes to the inhibition of T cell activation and promotes an immunosuppressive microenvironment [12]. Targeting OTUD3 could therefore present a promising strategy to reverse T cell exhaustion and improve response to immunotherapies. Regulation of antiviral immunity OTUD3 plays a crucial role in immune cell function through its deubiquitinating enzyme activity. It orchestrates antiviral responses by selectively controlling the stability and activity of key signaling proteins. For instance, OTUD3 curbs excessive innate immune activation by directly deubiquitinating MAVS [39]. Conversely, it enhances the response to DNA viruses by interacting with and stabilizing cGAS, thereby boosting its enzymatic activity. This protective role is clearly demonstrated during HSV-1 infection, where OTUD3 deficiency leads to rampant viral replication and a sharp decline in antiviral factors like IFN-β and CXCL1042. Intriguingly, OTUD3 plays a dualistic role in antiviral immunity, a finding that highlights the sophistication of host defense strategies. It acts as a negative regulator for RNA viruses by modulating the RIG-I/MDA5 pathway while simultaneously promoting the immune response against DNA viruses via cGAS [38]. This opposing functionality reveals OTUD3 as a pivotal molecular switch that helps tailor the innate immune response to the specific nature of the viral threat. Mechanisms of immune evasion mediated by OTUD3 OTUD3 promotes tumor immune evasion across a spectrum of cancers by stabilizing immunosuppressive proteins, with its role in regulating PD-L1 being particularly critical. The most direct evidence comes from diffuse DLBCL, where OTUD3 is upregulated and directly deubiquitinates and stabilizes PD-L1. This action leads to PD-L1 accumulation on the tumor cell surface, which engages PD-1 on CD8⁺ T cells, inhibits their cytotoxic function, and drives them into exhaustion, thereby facilitating immune escape. The functional importance of this axis is underscored by the finding that the drug Rupatadine inhibits OTUD3, promotes PD-L1 degradation, and restores anti-tumor immunity in DLBCL models [12]. The significance of OTUD3 is further highlighted when viewed against the backdrop of PD-L1-mediated immune evasion in other malignancies. Although the mitochondrial gene NDUFB10 has been identified as an immune regulator in lung adenocarcinoma [57], PD-L1 upregulation remains the key mechanism mediated by oncogenic EGFR signaling in EGFR-driven lung tumors [58]. By contrast, in melanoma, PD-L1 expression is induced by IFN-γ released from tumor-infiltrating lymphocytes as part of an adaptive resistance mechanism [59]. Similarly, in HPV-associated head and neck squamous cell carcinoma, PD-L1 expression at the tumor-stroma interface creates an immunosuppressive frontier [60], and in acute myeloid leukemia, PD-L1 expressed on regulatory B cells is associated with T cell function [61]. In parallel, In esophageal squamous cell carcinoma, tumor-derived small extracellular vesicles expressing PD-L1 (sEV-PDL1) directly exhaust CD8⁺ T cells and suppress effector molecules, fostering an immunosuppressive microenvironment that is reversible by anti-PDL1 treatment [62]. This PD-L1-mediated immunosuppression is further modulated by the tumor’s intrinsic properties, as evidenced by recent findings that a low DNA damage repair-associated signature (DAS) correlates with improved prognosis, enhanced immune infiltration, and better response to immunotherapy [63]. These diverse mechanisms across different cancers illustrate the universal importance of PD-L1 in immune evasion. Notably, in anaplastic thyroid carcinoma, PD-L1 is expressed in 68.2% of cases and is associated with poorer survival, further underscoring its role in immune escape across cancer types [64], as supported by recent research on thyroid cancer molecular subtypes (Zhang et al., 2025). Among the various pathways that regulate PD-L1 stability—including transcriptional upregulation and other post-translational modifications—OTUD3 stands out as a direct enzymatic stabilizer, positioning it as a central node in this network. Beyond its role in adaptive immunity via PD-L1, OTUD3 also modulates innate immune responses by deubiquitinating MAVS, thereby curbing antiviral signaling and suggesting a broader role in immune suppression [39]. OTUD3 as an immunotherapeutic target The rise of cancer immunotherapy has brought increasing recognition to the prognostic value of OTUD3 and its potential as a therapeutic target. Analytical approaches like weighted gene co-expression network analysis (WGCNA) have identified OTUD3 as a key metastasis-associated gene in UM. It is part of a four-gene signature (with UBXN2B, KAT8, and LAMTOR2) that robustly stratifies patients into high- and low-risk groups [36]. Elevated OTUD3 expression correlates strongly with poorer overall survival and an immune-evasive tumor microenvironment characterized by enriched infiltration of γδ T cells [36]. These findings collectively position OTUD3 not merely as a passenger gene, but as an active driver of poor prognosis across malignancies, which it achieves by post-transcriptionally regulating key mRNAs to impact the metastatic niche. Given its critical role in promoting immune evasion across multiple cancer types, targeting OTUD3 represents a promising strategy to enhance the efficacy of existing immunotherapies. In DLBCL, the anti-allergy drug Rupatadine has been shown to function as a competitive inhibitor of OTUD3, thereby reducing PD-L1 stability, reversing T cell exhaustion, and restoring antitumor immunity, both in vitro and in vivo [12]. This suggests that pharmacological inhibition of OTUD3 could sensitize tumor cells to immune checkpoint blockade by lowering PD-L1 levels and reinvigorating CD8⁺ T-cell activity. Similarly, in HPV-associated head and neck squamous cell carcinoma and melanoma, PD-L1 expression is driven by inflammatory signals such as IFN-γ in the tumor microenvironment [58–60], indicating that OTUD3-mediated stabilization of PD-L1 may serve as a common post-translational mechanism underlying adaptive immune resistance. Moreover, in acute myeloid leukemia, PD-L1 expression on regulatory B cells contributes to T cell suppression and poor prognosis [61], further supporting the broad relevance of the PD-1/PD-L1 axis across malignancies. Therefore, OTUD3 could serve as a valuable predictive biomarker and therapeutic target not only in liver cancer but also in a range of other cancers. Future efforts should focus on developing specific OTUD3 inhibitors and evaluating their combination with anti-PD-1/PD-L1 antibodies to reverse immune evasion and improve clinical outcomes across different tumor types. OTUD3 in metabolism The deubiquitinating enzyme OTUD3 plays a critical role in regulating metabolic pathways and has significant implications in cancer biology (Fig. 3). It stabilizes key metabolic proteins by removing ubiquitin chains, thereby directly shaping the metabolic profile of cancer cells. Fig. 3Mechanisms of OTUD3 in Metabolism Mechanisms of OTUD3 in Metabolism In general metabolism, OTUD3 regulates lipid and glucose metabolism by stabilizing PPARδ and helps maintain iron homeostasis through the stabilization of IRP2. In cancer, OTUD3 exhibits context-dependent functions. It suppresses mTORC1 signaling and glycolytic flux by stabilizing KPTN. In clear cell renal cell carcinoma, OTUD3 stabilizes SLC7A11 to inhibit ferroptosis and confer resistance to sunitinib. Meanwhile, in lung adenocarcinoma, it is recruited by BUB1B to stabilize NRF2, thereby promoting antioxidant gene expression and conferring chemotherapy resistance. OTUD3 in general metabolic regulation OTUD3 is fundamentally involved in maintaining cellular metabolic homeostasis. A key mechanism involves its direct regulation of peroxisome proliferator-activated receptor delta (PPARδ), a master transcriptional regulator of lipid and glucose metabolism. Upon nutrient stimulation, OTUD3 itself undergoes acetylation and translocates to the nucleus, where it interacts with and stabilizes PPARδ [15]. This nuclear action directly fine-tunes the expression of metabolic genes, thereby orchestrating adaptive responses to fluctuating metabolic demands. Beyond its role in lipid and glucose metabolism, OTUD3 is a critical regulator of iron homeostasis. It maintains iron metabolic balance by stabilizing Iron Regulatory Protein 2 (IRP2), a key regulator of cellular iron uptake and storage [41, 65]. The functional significance of the OTUD3-IRP2 axis is particularly evident in pathological states. For instance, during cerebral ischemia-reperfusion injury, OTUD3-mediated stabilization of IRP2 inhibits the p53/PTGS2 pathway, a process that reduces ferroptosis in hippocampal neurons and ameliorates neuronal damage [65]. Although this protective mechanism was characterized in a neurological context, it underscores OTUD3’s broad importance in metabolic regulation across diverse cell types. Furthermore, recent evidence has elucidated another critical pathway through which OTUD3 influences cellular metabolism and survival: the regulation of ferroptosis. In clear cell renal cell carcinoma (ccRCC), OTUD3 confers resistance to the tyrosine kinase inhibitor sunitinib by directly deubiquitinating and stabilizing the cystine/glutamate transporter SLC7A11. This OTUD3-SLC7A11 axis enhances cystine uptake, facilitates glutathione synthesis, and suppresses deleterious lipid peroxidation, ultimately inhibiting ferroptosis [66]. This mechanism not only positions OTUD3 at the nexus of iron metabolism and cell survival but also highlights the OTUD3-SLC7A11 axis as a promising therapeutic target for overcoming drug resistance in ccRCC. OTUD3 in cancer metabolism OTUD3 plays a complex and context-dependent role in cancer metabolism. In lung adenocarcinoma, BUB1b recruits OTUD3 to deubiquitinate and stabilize NRF2, thereby enhancing the expression of downstream antioxidant genes (e.g., SLC7A11, GPX4, HO-1) and promoting resistance to ferroptosis and chemotherapy [67]. However, the underlying mechanism is distinct. In ccRCC, OTUD3 directly interacts with and stabilizes SLC7A11 via deubiquitination, increasing cystine uptake and glutathione synthesis to suppress lipid peroxidation and ferroptosis, thereby conferring resistance to sunitinib [66]. By deubiquitinating and stabilizing KPTN, a key component of the KICSTOR complex, OTUD3 suppresses mTORC1 activity [13], thereby inhibiting oncogenic metabolic activation. This suppression reprograms core metabolic pathways in cancer cells, limiting nutrient acquisition and macromolecule synthesis. A major outcome of OTUD3-mediated mTORC1 suppression is reduced glycolytic flux. Since mTORC1 hyperactivation drives the Warburg effect—a hallmark of cancer metabolism [68, 69], it is plausible that OTUD3 lowers glucose consumption and lactate production by suppressing mTORC1 signaling. This effect occurs in both solid tumors and hematologic malignancies, where mTOR facilitates metabolic adaptation and therapy resistance [70, 71]. OTUD3 is also proposed to restrict mTORC1-driven lipogenesis, a key anabolic process in many cancers. mTORC1 promotes fatty acid synthesis via SREBP1c and enzymes such as ATP-citrate lyase (ACLY) [72]. OTUD3 likely counteracts this program, impairing de novo lipid synthesis and lipid droplet formation—a particular vulnerability in lipid-dependent cancers. This aligns with observations in prostate cancer, where mTOR supports lipid and amino acid metabolism for progression and treatment resistance [73]. The physiological relevance of OTUD3 is notable in metabolic disorder-associated cancers such as HCC. In NAFLD/MAFLD, which promotes hepatocarcinogenesis via lipid accumulation and inflammation [74–78], OTUD3 may fine-tune mTORC1 activity as a metabolic checkpoint, thereby opposing tumor development. Interplay between Inflammation, immune and metabolism networks in OTUD3 OTUD3 bridges metabolism and immune responses OTUD3 plays a pivotal role in maintaining metabolic balance by stabilizing key proteins such as PPARδ and IRP2, which regulate lipid, glucose, and iron metabolism [15, 41]. These metabolic processes are not only essential for cellular energy homeostasis but also directly influence immune cell function and energy availability within the tumor microenvironment. Through its deubiquitinating activity, OTUD3 thereby connects metabolic states to immune responsiveness. Simultaneously, OTUD3 directly regulates immune signaling pathways, such as cGAS-STING. It enhances antiviral immunity against DNA viruses by stabilizing cGAS and promoting IFN-β production [42]. This dual regulatory capacity positions OTUD3 at the intersection of metabolic and immune adaptation, enabling it to fine-tune both systems in response to cellular stress or pathogenic challenge. Moreover, OTUD3’s involvement in immune contexture is highlighted in cancers such as uveal melanoma, where its expression correlates with specific immune infiltrates like γδ T cells [36], further linking its metabolic functions to immune modulation. These metabolic processes directly influence immune cell function and energy availability in the tumor microenvironment. OTUD3 connects immune and inflammatory pathways OTUD3 emerges as a critical nexus, strategically positioned to couple the initiation of immune signaling with the modulation of inflammatory outcomes. In antiviral innate immunity, OTUD3 constrains excessive inflammation by deubiquitinating the mitochondrial adaptor MAVS. This action represses MAVS aggregation, thereby attenuating the downstream activation of transcription factors IRF3 and NF-κB and ultimately limiting the production of type I interferons and pro-inflammatory cytokines [39]. This mechanism directly links pathogen sensing to the calibrated control of inflammatory output. Similarly, within the colonic microenvironment, OTUD3-mediated deubiquitination of STING in fibroblasts acts as a crucial brake, preventing microbiota-driven immune activation from escalating into destructive inflammation, as exemplified in ulcerative colitis [40]. Conversely, OTUD3 can also potentiate host defense by stabilizing the cytosolic DNA sensor cGAS. This enhancement of the cGAS-STING axis amplifies the production of both type I interferons and inflammatory chemokines, demonstrating its capacity to coordinately upregulate antiviral and inflammatory arms of the immune response [42]. Genetic evidence further underscores OTUD3’s role at the immune-inflammation interface. Genome-wide association studies have identified OTUD3 as a susceptibility locus for ulcerative colitis, implicating its variants in the pathogenesis of immune-mediated inflammatory disease [45]. Complementary functional genomics approaches reveal that OTUD3 expression shapes transcriptional programs in intestinal epithelial cells, enriching for genes involved in antiviral defense and type I interferon signaling [46]. This directly positions OTUD3 at the crossroads of immune triggering and the ensuing inflammatory gene expression. Collectively, through its context-dependent regulation of pivotal signaling hubs—MAVS, STING, and cGAS—OTUD3 functions as a master integrator. It fine-tunes the magnitude of immune activation to govern the subsequent inflammatory pathology, ensuring that host defense is balanced against the risk of collateral tissue damage. OTUD3 links inflammatory signaling to metabolic homeostasis The deubiquitinase OTUD3 plays a critical role in linking inflammatory signaling to metabolic regulation. This is evident not only in cerebral ischemia–reperfusion injury—where OTUD3 stabilizes IRP2 to regulate iron metabolism and suppress ferroptosis by inhibiting the p53/PTGS2 pathway [65]—but also in other inflammatory metabolic disorders. For instance, in diabetic retinopathy, loss of OTUD3 exacerbates TNF-α–driven inflammation, leading to oxidative stress and impaired PPARγ function [16], while in bronchopulmonary dysplasia(BPD), OTUD3 upregulation stabilizes PTEN, contributing to inflammatory lung injury [48]. These findings illustrate that OTUD3 sits at the intersection of inflammation and metabolism: inflammatory conditions can alter metabolic gene expression via OTUD3, and conversely, metabolic stressors such as a high-fat diet can modulate OTUD3 acetylation and nuclear translocation [15], affecting inflammatory gene expression. Through its ability to deubiquitinate key substrates, OTUD3 fine-tunes these interconnected systems. Its role as a molecular bridge that helps to maintain the bidirectional regulatory loop between inflammation and metabolic homeostasis is further demonstrated by its capacity to restore redox balance and glutathione metabolism [65]. Dual roles of OTUD3 in cancer cell Proliferation, Invasion, and metastasis Dual roles in cell proliferation OTUD3 primarily functions as a tumor suppressor in several cancer types through its ability to modulate multiple signaling hubs. This is particularly evident in hepatocellular carcinoma, where OTUD3 curbs the ISR by stripping K27-linked polyubiquitin chains from eIF2α—a mechanism that effectively stalls tumor progression and chemoresistance. This protective function is evident in OTUD3-knockout mice, which exhibit accelerated hepatocarcinogenesis [28]. Beyond this pathway, OTUD3 exerts its protective role by deubiquitinating and stabilizing the phosphatase PTEN, thereby dampening the oncogenic PI3K-AKT signaling axis and restraining tumor growth [33]. A further layer to its anti-tumor activity was revealed with the discovery that OTUD3 targets KPTN to suppress mTORC1 signaling, solidifying its role as a multi-faceted brake on proliferation [13]. Paradoxically, OTUD3 exhibits a context-dependent oncogenic function, promoting cell proliferation in other tissues. The dichotomous nature of this enzyme becomes apparent in hematopoietic malignancies. Here, OTUD3 is implicated in driving the proliferation of blood and lymphocyte cells, and its elevated expression correlates with poor survival, marking it as a potential adversary in these contexts [79]. Similarly, in cholangiocarcinoma, OTUD3-mediated stabilization of the transcription factor ARID3A is a key driver of malignancy, and the co-upregulation of this duo predicts unfavorable patient outcomes [22]. CRC provides another example of its tumor-promoting face, where OTUD3 deubiquitinates and stabilizes the transcription factor YY1, an activity that supports tumorigenesis [23]. This striking functional dichotomy underscores that the biological outcome of OTUD3 activity is not intrinsic but is critically defined by the cellular and tissue landscape. Dual role of OTUD3 in cancer metastasis and invasion The influence of OTUD3 extends to cancer cell migration and invasion, pivotal steps in metastasis. In esophageal carcinoma, nicotine-induced OTUD3 downregulation leads to destabilization of ZFP36, resulting in VEGF-C overexpression and consequently promoting lymph angiogenesis and metastasis [9]. Conversely, in lung adenocarcinoma, OTUD3 enhances invasion and metastatic potential by stabilizing GRP78 and sustaining its high expression levels [11]. This is further supported by the finding that the ubiquitin ligase CHIP targets OTUD3 for degradation, thereby suppressing the OTUD3-GRP78 signaling axis and inhibiting lung cancer metastasis [31]. Additionally, a recent study demonstrates that OTUD3 inhibits breast cancer metastasis by deubiquitinating and stabilizing SMAD7, thereby suppressing the TGF-β signaling pathway and epithelial-mesenchymal transition (EMT) [20]. In papillary thyroid carcinoma, BGL3 recruits OTUD3 to enhance PTEN deubiquitination and stability, thereby inhibiting tumor progression [37]. These findings highlight OTUD3’s complex involvement in metastatic regulation and suggest that its targeting may hold therapeutic promise in specific cancer types (Fig. 4). Fig. 4The Dual Roles of OTUD3 in Cancer Progression The Dual Roles of OTUD3 in Cancer Progression (Oncogenic Role): OTUD3 promotes tumor progression by stabilizing key oncogenic proteins: it stabilizes GRP78 to facilitate metastasis in lung cancer (a process negatively regulated by the E3 ligase CHIP); stabilizes ARID3A to drive proliferation and invasion in cholangiocarcinoma; stabilizes ACTN4 to enhance proliferation, invasion, and metastasis in liver cancer; and stabilizes YY1 in colorectal cancer, which subsequently activates the TNNB1/β-catenin pathway and inhibits miR-500a-5p, thereby promoting proliferation and colony formation (a process enhanced by PLK1 kinase). (Tumor-Suppressive Role): OTUD3 inhibits cancer progression through multiple mechanisms: in esophageal cancer, nicotine exposure reduces OTUD3, leading to ZFP36 degradation via K48-linked ubiquitination and subsequent VEGF-C-mediated lymphangiogenesis; it suppresses the mTORC1 pathway via KPTN to inhibit tumor cell growth; in liver cancer, it inhibits the Integrated Stress Response (ISR) by reducing eIF2α phosphorylation and ATF4 expression, thereby suppressing proliferation and tumorigenesis; and in breast cancer, it stabilizes SMAD7 to inhibit the TGF-β/SMAD2/3 signaling pathway, consequently suppressing invasion, metastasis, and proliferation. A case study in complexity: dual mechanisms in HCC and CRC The role of deubiquitinating enzymes in cancer is often context-dependent, yet it is rare for a single enzyme to display directly opposing functions across different cancer types. A focused examination of HCC and CRC reveals that OTUD3 is a dual-functioning enzyme, capable of acting as either an oncogene or a tumor suppressor depending on specific cellular conditions. This unique duality makes it a fascinating case study in cancer complexity. HCC exemplifies the intricate nature of OTUD3 regulation. On one hand, it constrains proliferation through deubiquitination of eIF2α and suppression of the ISR pathway, disrupting productive EIF2AK3 engagement and limiting tumor growth [28]. On the other hand, OTUD3 enhances HCC progression by stabilizing ACTN4 [29]. This dualism—both restraining and driving HCC malignancy—illustrates the nuanced, pleiotropic functions of OTUD3 and highlights the OTUD3-ACTN4 axis as a promising target for controlling advanced HCC (Table 4). In CRC, OTUD3 also exhibits dual, context-dependent roles. Its primary oncogenic function involves stabilizing the transcription factor YY1. OTUD3 directly binds to and deubiquitinates YY1, preventing its proteasomal degradation. This enhances the expression of oncogenes like c-Myc and EGFR, promoting tumor growth—a process potentiated by PLK1-mediated phosphorylation [23]. Conversely, OTUD3 also shows tumor-suppressive properties. It is a direct target of oncogenic miR-32, and its downregulation promotes proliferation, migration, and inhibits apoptosis. Silencing OTUD3 mimics miR-32’s effects, indicating that OTUD3 can also restrain tumorigenic behaviors in certain contexts [30]. This contradiction highlights OTUD3’s role as shaped by specific cellular pathways and targets. Table 4Dual role of OTUD3 in HCC and CRCRegulatory effectMolecular mechanismTargetsBiological outcomeInhibits proliferationOTUD3 removes K27-linked ubiquitin chains from eIF2α, blocking interaction with EIF2AK3 and suppressing eIF2α phosphorylation and ISR activationeIF2αSuppresses hepatocellular carcinoma cell proliferationm [28]Promotes proliferation, migration & invasionOTUD3 deubiquitinates and stabilizes α-actinin-4 (ACTN4)ACTN4Drives HCC proliferation, migration, invasion, and lung metastasis [29]Promotes tumor progressionOTUD3 directly binds to and deubiquitinates the transcription factor YY1YY1Promotes colorectal cancer cell proliferation, clone formation, and tumor growth in vivo [23]Downregulation of OTUD3OTUD3 mRNA is directly targeted and degraded by miR-32 binding to its 3’-UTRmiR-32Promotes cell proliferation and migration; suppresses apoptosis in colon cancer cells [30] Table 4Dual role of OTUD3 in HCC and CRCRegulatory effectMolecular mechanismTargetsBiological outcomeInhibits proliferationOTUD3 removes K27-linked ubiquitin chains from eIF2α, blocking interaction with EIF2AK3 and suppressing eIF2α phosphorylation and ISR activationeIF2αSuppresses hepatocellular carcinoma cell proliferationm [28]Promotes proliferation, migration & invasionOTUD3 deubiquitinates and stabilizes α-actinin-4 (ACTN4)ACTN4Drives HCC proliferation, migration, invasion, and lung metastasis [29]Promotes tumor progressionOTUD3 directly binds to and deubiquitinates the transcription factor YY1YY1Promotes colorectal cancer cell proliferation, clone formation, and tumor growth in vivo [23]Downregulation of OTUD3OTUD3 mRNA is directly targeted and degraded by miR-32 binding to its 3’-UTRmiR-32Promotes cell proliferation and migration; suppresses apoptosis in colon cancer cells [30] Dual role of OTUD3 in HCC and CRC Post-translational modifications (PTMs) of OTUD3 Effects of Phosphorylation, Acetylation, and ubiquitination on OTUD3 activity The functional versatility and pathophysiological roles of OTUD3 are critically shaped by PTMs, which dynamically regulate its stability, catalytic activity, and substrate recognition. Phosphorylation, acetylation, and ubiquitination represent key regulatory events that allow OTUD3 to fine-tune signaling across diverse cellular contexts (Fig. 5). Below, we explore how these PTMs modulate OTUD3 function in both normal physiology and disease, with emphasis on its dual roles in cancer, immunity, and metabolism. Fig. 5Regulatory Mechanisms of OTUD3 by Post-Translational Modifications Regulatory Mechanisms of OTUD3 by Post-Translational Modifications Phosphorylation serves as a molecular switch; GSK3β-mediated phosphorylation at Ser9 enables ARID3A binding and stabilization, while PLK1-mediated phosphorylation at Ser326 enhances YY1 affinity to promote cancer progression. The E3 ligase CHIP controls OTUD3 stability by targeting it for K48-linked ubiquitination and proteasomal degradation. Acetylation regulates OTUD3 localization and activity, whereby acetylated OTUD3 deubiquitinates MAVS to inhibit innate immunity and undergoes nuclear translocation to modulate metabolic gene expression. Phosphorylation modification of OTUD3 Phosphorylation acts as a molecular switch that controls OTUD3’s enzymatic function and substrate specificity, with significant implications in oncology and metabolic disease. A well-characterized example involves GSK3β-mediated phosphorylation at Ser9, which promotes OTUD3 binding to the transcription factor ARID3A. This interaction facilitates ARID3A deubiquitination and stabilization, driving proliferation and metastasis in cholangiocarcinoma (CCA). Crucially, Ser9 is essential for this function: GSK3β activation increased phosphorylation of wild-type OTUD3, but not an S9A mutant, while treatment with GSK3β inhibitors such as Tideglusib disrupted this axis. Clinically, elevated co-expression of OTUD3 and ARID3A correlates with poor prognosis in CCA, highlighting the translational relevance of this pathway [22]. Another phosphorylation site, Ser326, is regulated by PLK1 in CRC. Phosphorylation at this residue enhances OTUD3’s affinity for the transcriptional regulator YY1, increasing its deubiquitination and stability. This in turn amplifies YY1-mediated transcription and promotes CRC progression, suggesting that targeting phospho-Ser326-OTUD3 could offer new therapeutic avenues [23]. Acetylation modification of OTUD3 Acetylation provides another mechanism for regulating OTUD3, influencing its localization, interactions, and functional outcomes in immunity and metabolism. Notably, acetylated OTUD3 plays a restrictive role in early antiviral innate immunity. It attenuates the type I interferon response by deubiquitinating and inactivating MAVS, thereby setting a threshold for immune activation. This regulation prevents an overzealous immune response under steady-state conditions. Upon virus infection, the deacetylation and inactivation of OTUD3 by SIRT1 release this brake, allowing for a swift and effective antiviral defense. Consistent with this, OTUD3-deficient mice show enhanced innate immunity and reduced viral loads [39]. In metabolism, OTUD3 acetylation promotes its nuclear translocation, where it modulates transcriptional programs related to lipid and glucose homeostasis. OTUD3-knockout mice on a high-fat diet developed severe obesity, dyslipidemia, and insulin resistance, underscoring its role as a metabolic regulator that integrates nutritional cues with gene expression [15]. Ubiquitination modification of OTUD3 As a deubiquitinating enzyme, OTUD3 is itself regulated by ubiquitination, which affects its stability and functional adaptability across biological settings. A prime example of this regulation occurs in lung cancer, where OTUD3 can exhibit oncogenic properties. The ubiquitin ligase CHIP targets OTUD3 for K48-linked polyubiquitination, marking it for proteasomal degradation. However, when CHIP is downregulated or mutated, OTUD3 levels increase. The stabilized OTUD3 then deubiquitinates and stabilizes its substrate, GRP78, a chaperone protein that promotes tumor growth and metastasis. This CHIP-OTUD3-GRP78 axis illustrates how ubiquitination directly controls OTUD3’s stability to indirectly influence its dual function in cancer [31]. Ubiquitination adds yet another layer to the regulation of OTUD3, enabling rapid modulation of its activity in response to cellular signals. Through this PTM, OTUD3 participates in a wide array of processes—including tumor suppression, neuroprotection, and the maintenance of immune and metabolic homeostasis—making it a compelling target for mechanistic and therapeutic investigation. PTMs in tumorigenesis Immunotherapy for cancer remains challenging due to intricate immune evasion mechanisms within the tumor microenvironment (TME). Emerging studies identify PTMs as pivotal regulators of immune checkpoint crosstalk and immunocyte functionality. Notably, PD-1 phosphorylation at Thr234 suppresses T-cell activity, exemplifying PTM-mediated immunosuppression that drives cancer progression [80]. PD-L1 engagement induces phosphorylation of the Y248 residue within PD-1’s immunoreceptor tyrosine-based inhibitory motif (ITSM), a molecular hallmark of dysfunctional T cells in tumor-infiltrating lymphocytes (TILs). This phosphorylation-dependent modification disrupts T-cell receptor (TCR) signaling cascades, consequently impairing antitumor immunity [81]. Aberrant phosphorylation of STAT3 and ZAP70 drives immunosuppressive TME formation and T-cell dysfunction respectively, with STAT3 hyperactivation promoting immune tolerance while ZAP70 dysregulation impairs TCR signaling fidelity [82, 83]. N58 glycosylation of PD-1 enhances PD-L1 binding affinity, whereas CD47 glycosylation promotes tumor immune evasion via macrophage phagocytosis resistance, collectively illustrating glycosylation-mediated control of immune checkpoint networks [84, 85]. Glypican-3 (GPC3) glycosylation accelerates hepatocellular carcinoma progression via conformational stabilization of oncogenic signaling assemblies, demonstrating PTM-driven reprogramming of tumorigenic circuitry [86]. Acetylation activates NF-κB signaling through p65 Lys310 modification and enhances immune-related gene transcription via PD-L1 modulation [87, 88], while SUMOylation facilitates immune evasion by three direct or indirect mechanisms: p65 inhibition [89], IL-33-IRF1 axis amplification [90], and RNF146-driven Wnt/β-catenin activation [91]. Furthermore, lactylation activates pro-fibrotic hepatic stellate cells (HSCs) via HK2-dependent histone remodeling [92, 93] and amplifies TGF-β signaling in regulatory T cells (Tregs), collectively establishing an immune-tolerant tumor niche [94]. Targeting PTMs-including PD-L1 glycosylation inhibitors and STAT3 phosphorylation antagonists-offers therapeutic potential to circumvent resistance to immune checkpoint blockade. Future HCC treatment frameworks must synergize PTM-directed strategies with multimodal immunotherapies to maximize clinical efficacy [95]. OTUD3 orchestrates cholangiocarcinoma and CRC progression through multi-layered post-translational regulation, including phosphorylation exemplified by GSK3β/PLK1-mediated Ser9/Ser326 modifications that stabilize ARID3A/YY1, acetylation-dependent modulation of MAVS deubiquitination and metabolic gene nuclear translocation, along with ubiquitination dynamics. In hepatocellular carcinoma, diverse post-translational modifications synergistically drive immune evasion through remodeling PD-1/STAT3 signaling pathways, activating immune checkpoints, and shaping an immune-tolerant tumor microenvironment. These findings underscore the therapeutic potential of simultaneously targeting OTUD3-specific post-translational modifications to overcome immunotherapy resistance. Progress on OTUD3-targeted therapy In recent years, OTUD3, a deubiquitinating enzyme, has garnered significant attention in cancer research due to its dual regulatory roles in tumorigenesis. Accumulating evidence demonstrates that OTUD3 expression levels are closely associated with tumor initiation and progression across multiple cancer types, including hepatocellular carcinoma, breast cancer, and lung cancer. Mechanistic studies reveal that OTUD3 modulates critical oncogenic processes by deubiquitinating key regulatory proteins, thereby influencing cellular proliferation, apoptosis, and signal transduction pathways. These molecular interactions ultimately dictate tumor biological behaviors and clinical outcomes. Therapeutic exploitation of OTUD3’s dual functionality Extensive investigations into the functional mechanisms of OTUD3 have accelerated the development of targeted therapies against this deubiquitinating enzyme. Recent studies demonstrate that Rolapitant effectively inhibits OTUD3’s enzymatic activity, achieving dual therapeutic effects: substantial suppression of lung cancer cell proliferation and enhanced cellular responsiveness to TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through sensitization mechanisms [18]. Notably, elevated OTUD3 expression has been documented in DLBCL. Mechanistic analyses reveal that the OTUD3-targeting inhibitor Rupatadine exerts its anti-tumor effects through competitive enzymatic binding, which specifically impedes deubiquitination of both MYL12A and PD-L1. This coordinated suppression simultaneously disrupts malignant cell survival pathways and immune-evasion strategies, effectively countering two hallmark oncogenic processes in DLBCL progression [12]. The newly characterized OTUD3 inhibitor OTUDin3 exhibits dual anti-proliferative and pro-apoptotic efficacy across non-small cell lung cancer (NSCLC) cellular models, thereby underscoring the therapeutic relevance of OTUD3 in precision cancer therapeutics [32]. OTUD3 emerges as a clinically validated transcriptomic determinant predictive of therapeutic outcomes in NSCLC. Further molecular profiling reveals OTUD3’s functional coordination with SUCGL2 and RQCD1, establishing a superior three-marker prognostic panel that demonstrates enhanced predictive accuracy over conventional single-analyte assessments in adjuvant chemotherapy stratification [96]. OTUD3 emerges as a central epigenetic orchestrator of cancer chemoresistance through functional crosstalk with multiple microRNAs. Mechanistically, miR-520 h induces phosphorylation-dependent AKT activation via the OTUD3-PTEN regulatory axis, driving paclitaxel resistance in breast malignancies. Functionally, miR-520 h overexpression strongly predicts adverse clinical outcomes, establishing its dual role as both resistance mediator and prognostic biomarker [21]. miR-32 drives colorectal oncogenesis through direct OTUD3 targeting and transcriptional silencing, forming a potent regulatory axis that accelerates malignant progression [30]. Recurrent spontaneous abortion (RSA) patients exhibit significantly impaired trophoblast cell viability and migratory capacity. Mechanistically, miR-101-3p enhances trophoblast cell viability and migratory capacity while inhibiting apoptosis through OTUD3 suppression [97]. BPD persists as a predominant chronic condition in preterm infants. Experimental evidence indicates that murine BPD models demonstrate miR-34c-5p downregulation, concurrent OTUD3/PTEN upregulation, elevated IL-1β/IL-6 concentrations, and exacerbated inflammatory responses. Bone marrow stromal cell-derived extracellular vesicles deliver miR-34c-5p, ameliorating hyperoxia-induced pulmonary injury and inflammation in BPD mice by targeting OTUD3 to mediate PTEN degradation [48]. Targeted pharmacological modulation of OTUD3 has unveiled multifaceted intervention strategies with cross-disease therapeutic potential. Mechanistically, small-molecule inhibitors demonstrate context-specific efficacy: Rolapitant suppresses OTUD3’s deubiquitinating activity to exert anti-proliferative/pro-apoptotic effects in lung cancer, while Rupatadine competitively inhibits OTUD3-mediated MYL12A/PD-L1 deubiquitination, dually targeting tumor survival and immune evasion in lymphoma. The therapeutic validity of OTUD3 targeting is further corroborated by OTUDin3 in non-small cell lung carcinoma. Intriguingly, OTUD3 exhibits paradoxical disease-modulating duality-functioning as an oncogenic driver requiring direct inhibition in malignancies versus displaying protective roles through miRNA-mediated downregulation (e.g., miR-101-3p/miR-34c-5p) in recurrent miscarriage and pulmonary injury. Furthermore, OTUD3’s interplay with miR-520 h/miR-32 regulatory networks position it as a promising target for overcoming tumor drug resistance, while its distinct transcriptomic profiles enable chemotherapy response prediction. These collective advances establish OTUD3 as a dynamically versatile therapeutic node, catalyzing diversified development pipelines spanning direct enzymatic inhibitors to epigenetic modulation strategies (Fig. 6). Fig. 6Mechanisms of OTUD3 in Targeted Therapies and Disease Modulation Mechanisms of OTUD3 in Targeted Therapies and Disease Modulation This schematic summarizes the multifaceted roles of OTUD3 in cancer and other diseases, highlighting its modulation by small-molecule inhibitors and miRNAs. In cancer, OTUD3 acts as an oncogenic driver: Rolapitant inhibits OTUD3 to suppress lung cancer proliferation and enhance TRAIL-mediated apoptosis; Rupatadine competitively blocks OTUD3-mediated deubiquitination of MYL12A and PD-L1, targeting survival and immune evasion in DLBCL; and OTUDin3 exerts anti-proliferative and pro-apoptotic effects in NSCLC. Additionally, OTUD3 is involved in chemoresistance via miRNA networks: miR-520 h drives AKT activation and paclitaxel resistance in breast cancer through the OTUD3-PTEN axis, while miR-32 promotes colorectal oncogenesis by targeting OTUD3. In non-cancer contexts, OTUD3 displays protective roles: miR-34c-5p delivery via extracellular vesicles ameliorates BPD by targeting OTUD3 to reduce inflammation, and miR-101-3p enhances trophoblast viability and migration by suppressing OTUD3 in recurrent spontaneous abortion. Clinical application and future research While OTUD3 emerges as a promising therapeutic target, its clinical translation confronts critical challenges requiring resolution. Pharmacological validation of OTUD3 inhibitors must address selectivity profiles and safety parameters. Preclinical evidence confirms Rolapitant’s anti-tumor efficacy through OTUD3 inhibition in vitro, though definitive validation of its in vivo therapeutic durability and toxicological safety awaits controlled clinical trials [18]. Secondly, the observed heterogeneity in OTUD3 expression profiles across patient populations may drive interindividual disparities in therapeutic efficacy, mandating the integration of genetic profiling into clinical trial design. Furthermore, comprehensive investigation of OTUD3’s physiological functions in non-neoplastic cells remains essential to preclude potential cytotoxic effects. Notably, OTUD3 demonstrates functional dichotomy that complicates therapeutic development, manifesting tumor-promotive activity in specific malignancies while exhibiting tumor-suppressive behavior in others (Table 5). Consequently, systematic characterization of OTUD3’s tissue-specific regulatory mechanisms across diverse tumor subtypes and strategic identification of suitable patient cohorts for targeted therapies persist as pivotal challenges in translational oncology research. Future investigations should prioritize four key directions: First, elucidating the precise mechanisms underlying OTUD3’s functionality across malignancies to resolve its dual regulatory roles in oncogenesis and disease progression. Second, developing highly specific OTUD3-targeting agents through systematic preclinical-to-clinical translation to establish therapeutic safety profiles and clinical efficacy. Third, leveraging multi-dimensional integration of omics datasets to map OTUD3’s functional interplay with complementary molecular pathways, potentially identifying predictive biomarkers for precision oncology. Finally, deciphering OTUD3’s immunomodulatory functions within tumor stroma, particularly its cross-talk with adaptive immune components, could unveil innovative immunotherapeutic targets. By implementing systems-level integration of OTUD3’s pathobiological networks spanning carcinogenesis, immunoregulation, and metabolic reprogramming, subsequent research may enable the development of multimodal treatment paradigms with enhanced therapeutic precision. Personalized therapeutic paradigms constitute a pivotal advancement in precision oncology. OTUD3-directed precision medicine should be stratified through comprehensive genomic characterization and tumor immune microenvironment assessments. By implementing systematic profiling of OTUD3 expression patterns and companion biomarkers, clinicians could identify optimal candidates for OTUD3-targeted therapies. Therapeutically, multimodal therapeutic synergy may be achieved through rational combinations of OTUD3 inhibitors with molecularly targeted drugs or immune-modulating agents. Notably in DLBCL, where OTUD3-mediated PD-L1 deubiquitination mechanistically drives immune evasion, concurrent administration of OTUD3 inhibitors with PD-1/PD-L1 blockade agents shows particular promise for enhancing treatment responses [12]. While OTUD3 presents considerable translational promise as an oncotherapeutic target, overcoming existing pharmacological and biomarker development challenges remains imperative for successful clinical implementation. Table 5Dual targeting effects of OTUD3 in therapeutic interventionsRegulatory moleculeDirect/IndirectMechanism of actionTarget(s)Disease(s)Application(s)RolapitantDirectInhibits OTUD3 deubiquitinating activityOTUD3Lung cancerSuppresses cancer cell proliferation, enhances sensitivity to TRAIL-induced apoptosis [18]RupatadineDirectCompetitively binds OTUD3, reduces MYL12A/PD-L1 deubiquitinationOTUD3, MYL12A, PD-L1DLBCLInhibits tumor cell survival and immune escape [12]OTUDin3DirectInhibits OTUD3 activityOTUD3NSCLCAnti-proliferation, pro-apoptotic effects [32]miR-101-3pIndirectSuppresses OTUD3 expressionOTUD3RSAEnhances trophoblast cell viability/migration, inhibits apoptosis [97]miR-34c-5pIndirectTargets OTUD3 to reduce its expression, promotes PTEN degradationOTUD3, PTENBPDAlleviates lung injury and inflammation [48]miR-520 hIndirectActivates AKT pathway via OTUD3-PTEN axisOTUD3, PTEN, AKTBreast cancerDrives paclitaxel resistance; high expression correlates with poor prognosis [21]miR-32IndirectDirectly targets and suppresses OTUD3 expressionOTUD3Colon cancerDrives malignant phenotypes [30] Table 5Dual targeting effects of OTUD3 in therapeutic interventionsRegulatory moleculeDirect/IndirectMechanism of actionTarget(s)Disease(s)Application(s)RolapitantDirectInhibits OTUD3 deubiquitinating activityOTUD3Lung cancerSuppresses cancer cell proliferation, enhances sensitivity to TRAIL-induced apoptosis [18]RupatadineDirectCompetitively binds OTUD3, reduces MYL12A/PD-L1 deubiquitinationOTUD3, MYL12A, PD-L1DLBCLInhibits tumor cell survival and immune escape [12]OTUDin3DirectInhibits OTUD3 activityOTUD3NSCLCAnti-proliferation, pro-apoptotic effects [32]miR-101-3pIndirectSuppresses OTUD3 expressionOTUD3RSAEnhances trophoblast cell viability/migration, inhibits apoptosis [97]miR-34c-5pIndirectTargets OTUD3 to reduce its expression, promotes PTEN degradationOTUD3, PTENBPDAlleviates lung injury and inflammation [48]miR-520 hIndirectActivates AKT pathway via OTUD3-PTEN axisOTUD3, PTEN, AKTBreast cancerDrives paclitaxel resistance; high expression correlates with poor prognosis [21]miR-32IndirectDirectly targets and suppresses OTUD3 expressionOTUD3Colon cancerDrives malignant phenotypes [30] Dual targeting effects of OTUD3 in therapeutic interventions Conclusion OTUD3 has firmly established itself as a master regulatory node in cancer biology, yet its true character remains frustratingly context-dependent and resistant to simple categorization. The enzyme’s functional duality—acting as either a staunch tumor suppressor or a potent oncoprotein—is not merely an academic curiosity but the central determinant of its therapeutic potential. This dichotomy is fundamentally rooted in its substrate selectivity: in one cellular setting, it deubiquitinates and stabilizes PTEN or p53 to put the brakes on proliferation, while in another, it performs the same action on GRP78, YY1, or PD-L1 to fuel tumor growth, metastasis, and immune evasion. This stark contrast means that any therapeutic strategy targeting OTUD3 must be predicated on a precise diagnostic understanding of its dominant role within a specific tumor. The emergence of small-molecule inhibitors like Rolapitant and Rupatadine validates OTUD3 as a druggable target and highlights a promising path forward, particularly in combinational regimens with immunotherapy. However, the path is fraught with challenges. The most significant hurdle is not just developing potent inhibitors, but reliably identifying which patients harbor tumors that are “addicted” to the oncogenic functions of OTUD3. Without robust biomarkers to stratify patients, we risk inadvertently harming those whose tumors rely on OTUD3’s protective, tumor-suppressive functions. This underscores a critical need to move beyond merely detecting OTUD3 expression levels and toward functionally mapping its activity state and key substrate interactions in clinical samples. Looking ahead, the field must pivot to tackle the deeper mechanistic mysteries. What are the precise molecular switches—be it a specific phosphorylation by PLK1, an acetylation event, or a competing protein-protein interaction—that flip OTUD3 from a guardian to a saboteur? Unraveling this code will require moving from cell-line models to more complex in vivo systems that capture the full complexity of the tumor microenvironment. The ultimate goal is to advance from a one-size-fits-all approach to a context-informed precision medicine paradigm. Success in this endeavor will not only provide new weapons against cancer but will also offer a blueprint for targeting the many other context-dependent regulators that defy easy classification.